Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20230901006
TCTR20230901006
Completed
Phase 3

Efficacy of vaginal progesterone for maintenance therapy in arrested preterm labor: A Randomized Controlled Trial

Hatyai hospital0 sites80 target enrollmentSeptember 1, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspreterm labor at gestational age of 24 weeks to 33 weeks and 6 dayssuccessfully inhibited with Nifedipine as an acute phase tocolysis (arrested preterm labor)Preterm labor

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
preterm labor at gestational age of 24 weeks to 33 weeks and 6 dayssuccessfully inhibited with Nifedipine as an acute phase tocolysis (arrested preterm labor)
Sponsor
Hatyai hospital
Enrollment
80
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

High-dose vaginal progesterone, as a maintenance agent, efficiently prolongs latency delivery day, reduces the rate of preterm birth and improves birth weight. However, it fails to delay the shortening of the cervix and does not decrease the rate of NICU admission.

Registry
who.int
Start Date
September 1, 2023
End Date
July 31, 2023
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Pregnant women presented with preterm labor at gestational age of 24 completed weeks to 33 weeks and 6 days

Exclusion Criteria

  • •lethal fetal anomaly
  • •dead fetus in utero
  • •non\-reassuring fetal status
  • •preeclampsia with severe features
  • •unstable maternal vital signs
  • •chorioamnionitis
  • •patient allergic to progesterone or progestrogen
  • •multifetal gestations
  • •placenta previa
  • •cervical os open more than 4 cm

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Vaginal Progesterone Supplementation in the Management of Preterm LaborPreterm Labor
NCT03202836Chulalongkorn University90
Active, not recruiting
Not Applicable
Progesterona vaginal como tratamiento de mantenimiento en gestantes con amenaza de parto pretérmino. Ensayo clínico aleatorizado, enmascarado a doble ciego y controlado con placebo - PROMESAAmenaza de parto pretérminoMedDRA version: 9.1Level: LLTClassification code 10043509Term: Threatened premature labor
EUCTR2007-005665-35-ESMontse Palacio Riera - Hospital Clínic de Barcelona - Maternitat
Active, not recruiting
Phase 1
Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, open, randomized trial.
CTIS2024-512844-40-00Vaestra Goetalandsregionen1,800
Recruiting
Phase 4
Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, open, randomized trial.
2024-512844-40-00Vaestra Goetalandsregionen1,800
Terminated
Phase 3
Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm LaborPreterm DeliveryMorbidityPerinatal Mortality
NCT00536003begoña Martinez de Tejada384